Compare Moderna, Inc. (MRNA) vs Workday Inc (WDAY) Price & Performance

Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.

The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.

Workday (WDAY) trades at $187.81, up 1.93% on the day, with a neutral technical signal and bullish moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $8.45B in 2025, and net income margin improved to 12.32%. Recent news highlights AI product launches and strategic partnerships, alongside a 2.5% headcount reduction aimed at realigning for growth.

WDAY presents a growth opportunity driven by AI integration and expanding market presence, but faces risks from competitive pressures and execution challenges. Analyst consensus is bullish with a $202.92 price target, though valuation multiples remain elevated. Investors should weigh strong fundamentals against potential volatility from market sentiment and operational adjustments.